Captrust Financial Advisors Crispr Therapeutics Ag Transaction History

Captrust Financial Advisors

$33 Billion
Q3 2024

A detailed history of Captrust Financial Advisors transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Captrust Financial Advisors holds 31,712 shares of CRSP stock, worth $1.56 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

31,712

Previous 24,024 32.0%

Holding current value

$1.56 Million

Previous $1.3 Million 14.88%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$44.62 - $62.75 $343,038 - $482,422	7,688 Added 32.0%	31,712 $1.49 Million
Q2 2024 Aug 14, 2024	SELL	$51.17 - $68.18 $72,610 - $96,747	-1,419 Reduced 5.58%	24,024 $1.3 Million
Q1 2024 May 15, 2024	SELL	$60.67 - $89.12 $75,655 - $111,132	-1,247 Reduced 4.67%	25,443 $1.73 Million
Q4 2023 Feb 14, 2024	BUY	$38.62 - $72.18 $34,024 - $63,590	881 Added 3.41%	26,690 $1.67 Million
Q3 2023 Nov 14, 2023	BUY	$45.39 - $59.0 $71,353 - $92,748	1,572 Added 6.49%	25,809 $1.17 Million
Q2 2023 Aug 14, 2023	SELL	$43.47 - $67.77 $74,724 - $116,496	-1,719 Reduced 6.62%	24,237 $1.36 Million
Q1 2023 May 15, 2023	SELL	$41.0 - $56.12 $10,496 - $14,366	-256 Reduced 0.98%	25,956 $1.17 Million
Q4 2022 Feb 15, 2023	BUY	$39.19 - $65.67 $27,472 - $46,034	701 Added 2.75%	26,212 $1.07 Million
Q3 2022 Nov 16, 2022	BUY	$61.1 - $83.78 $105,519 - $144,688	1,727 Added 7.26%	25,511 $1.67 Million
Q2 2022 Aug 23, 2022	SELL	$43.23 - $73.83 $148,019 - $252,793	-3,424 Reduced 12.58%	23,784 $1.45 Million
Q2 2022 Aug 16, 2022	BUY	$43.23 - $73.83 $269,063 - $459,517	6,224 Added 29.66%	27,208 $1.65 Million
Q1 2022 May 16, 2022	SELL	$53.19 - $79.24 $212,760 - $316,960	-4,000 Reduced 16.01%	20,984 $1.32 Million
Q4 2021 Feb 14, 2022	BUY	$70.09 - $111.29 $526,936 - $836,678	7,518 Added 43.04%	24,984 $1.89 Million
Q3 2021 Nov 16, 2021	SELL	$110.2 - $156.64 $415,784 - $591,002	-3,773 Reduced 17.76%	17,466 $1.96 Million
Q2 2021 Aug 16, 2021	SELL	$100.84 - $161.89 $81,781 - $131,292	-811 Reduced 3.68%	21,239 $3.44 Million
Q1 2021 May 17, 2021	BUY	$110.72 - $210.04 $531,123 - $1.01 Million	4,797 Added 27.8%	22,050 $2.69 Million
Q4 2020 Feb 16, 2021	SELL	$79.67 - $173.23 $17,925 - $38,976	-225 Reduced 1.29%	17,253 $2.64 Million
Q3 2020 Nov 17, 2020	SELL	$78.5 - $100.64 $137,139 - $175,818	-1,747 Reduced 9.09%	17,478 $1.46 Million
Q2 2020 Aug 14, 2020	BUY	$38.5 - $76.05 $27,373 - $54,071	711 Added 3.84%	19,225 $1.51 Million
Q1 2020 May 15, 2020	BUY	$33.68 - $62.53 $127,142 - $236,050	3,775 Added 25.61%	18,514 $713,000
Q4 2019 Feb 14, 2020	BUY	$36.68 - $73.13 $503,946 - $1 Million	13,739 Added 1373.9%	14,739 $874,000
Q1 2019 May 15, 2019	BUY	$28.02 - $40.87 $28,020 - $40,870	1,000 New	1,000 $36,000
Q3 2018 Nov 15, 2018	SELL	$44.35 - $65.71 $3,592 - $5,322	-81 Closed	0 $0
Q2 2018 Aug 13, 2018	BUY	$42.62 - $73.59 $3,452 - $5,960	81 New	81 $5,000

Others Institutions Holding CRSP

# of Institutions

493

Shares Held

58M

Call Options Held

1.1M

Put Options Held

1.9M

View Full List

About CRISPR Therapeutics AG

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.85B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

More about CRSP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Captrust Financial Advisors with notifications on news.

Account

Captrust Financial Advisors Crispr Therapeutics Ag Transaction History